H.R. 6833 117th Congress
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
- Became Public Law 117-180
- Economics and Public Finance
- Sponsor: Angie Craig
- Congress.gov ↗
Latest action, Sep 30, 2022: Became Public Law No: 117-180.
How the House voted: On Motion to Concur in the Senate Amendment
Sep 30, 2022 · Passed · 230–201 (it needed 1/2)
- Yea (230)
- Nay (201)
- Didn't vote (2)
- Letters: party (D, R, I)
By party
- Democrat
- Republican
- Independent
Every roll call on it (3)
Each dot is a roll call, in order: how much of the House voted yea. The ringed one decided it.
- Carried
- Failed
See the data
| Date | Question | Result | Yea–nay |
|---|---|---|---|
| Sep 30, 2022 | On Motion to Concur in the Senate Amendment | Passed | 230–201 |
| Mar 31, 2022 | On Passage | Passed | 232–193 |
| Mar 31, 2022 | On Motion to Recommit | Failed | 197–225 |
31 cosponsors
Sponsored by Angie Craig (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
31 D · 0 R
- Democrat
- Republican
- Independent
Referred to: House: Education and the Workforce Committee; House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
AARP, INC.
MEHLMAN CONSULTING, INC.
4 reports
AMERICA'S HEALTH INSURANCE PLANS
MEHLMAN CONSULTING, INC.
4 reports
4 reports
4 reports
AMERICAN MEDICAL ASSOCIATION
AVENUE SOLUTIONS
4 reports
AMERIHEALTH CARITAS
GREENBERG TRAURIG, LLP
4 reports
BLUE CROSS BLUE SHIELD ASSOCIATION
AVENUE SOLUTIONS
4 reports
4 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING
MCDERMOTT+ LLC
4 reports
CIGNA CORPORATION
INVARIANT LLC
4 reports
4 reports
ELEVANCE HEALTH, INC.
TIBER CREEK GROUP
4 reports
4 reports
GENENTECH USA, INC.
AVENUE SOLUTIONS
4 reports
The top 25 of 467 clients, by reports
| Client | Lobbying firm | Reports | Reports totaling | From | To | House |
|---|---|---|---|---|---|---|
| AARP, INC. | MEHLMAN CONSULTING, INC. | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| AMERICA'S HEALTH INSURANCE PLANS | MEHLMAN CONSULTING, INC. | 4 | $360K | Q1 2022 | Q3 2022 | yes |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 4 | $13.3M | Q1 2022 | Q3 2022 | yes | |
| AMERICAN BENEFITS COUNCIL | 4 | $1.3M | Q1 2022 | Q3 2022 | yes | |
| AMERICAN FEDERATION OF TEACHERS | 4 | $1.4M | Q1 2022 | Q3 2022 | yes | |
| AMERICAN MEDICAL ASSOCIATION | AVENUE SOLUTIONS | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| AMERIHEALTH CARITAS | GREENBERG TRAURIG, LLP | 4 | $120K | Q1 2022 | Q3 2022 | yes |
| BLUE CROSS BLUE SHIELD ASSOCIATION | AVENUE SOLUTIONS | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| CAMBIA HEALTH SOLUTIONS | 4 | $2.0M | Q1 2022 | Q3 2022 | yes | |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING | MCDERMOTT+ LLC | 4 | $120K | Q1 2022 | Q3 2022 | yes |
| CIGNA CORPORATION | INVARIANT LLC | 4 | $360K | Q1 2022 | Q3 2022 | yes |
| ELEVANCE HEALTH, INC. | 4 | $6.5M | Q1 2022 | Q3 2022 | yes | |
| ELEVANCE HEALTH, INC. | TIBER CREEK GROUP | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| ELI LILLY AND COMPANY | 4 | $6.8M | Q1 2022 | Q3 2022 | yes | |
| GENENTECH USA, INC. | AVENUE SOLUTIONS | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| HEALTHCARE LEADERSHIP COUNCIL | AVENUE SOLUTIONS | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| INCYTE CORPORATION | AVENUE SOLUTIONS | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| IOVANCE BIOTHERAPEUTICS, INC. | AVENUE SOLUTIONS | 4 | $50K | Q1 2022 | Q3 2022 | yes |
| JOHNSON & JOHNSON SERVICES, INC. | THE NICKLES GROUP, LLC | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| MERCK & CO. INC. | AVENUE SOLUTIONS | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS | 4 | $1.3M | Q1 2022 | Q3 2022 | yes | |
| NFIB (NATIONAL FEDERATION OF INDEPENDENT BUSINESS) | 4 | $4.1M | Q1 2022 | Q3 2022 | yes | |
| NOVO NORDISK INC. | 4 | $4.6M | Q1 2022 | Q3 2022 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 4 | $8.7M | Q1 2022 | Q3 2022 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 4 | $28.3M | Q1 2022 | Q3 2022 | yes |